Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biosynthesis, discovery, and biocatalytic production of halogenated nucleosides and nucleoside-sulfamates.

Award Number: R35GM162070
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2031

Group Awards By:

View Award Description

Biosynthesis, discovery, and biocatalytic production of halogenated nucleosides and nucleoside-sulfamates. - Project Summary. Nucleoside analogs are an important class of pharmaceutical compounds that serve as the cornerstone for antiviral therapy. Beyond viral infections, various nucleoside analogs have also shown antitumor, antibacterial, antifungal, and herbicidal activity. Though synthetic chemists can design new nucleoside analogs de novo, a large fraction of our pharmaceuticals are inspired by bioactive compounds made by bacteria. The proposed work will investigate the biosynthesis of a cryptic family of natural product nucleoside analogs that contain ‘rare’ functional groups. This work will be enabled by the research group’s expertise on non-standard nucleoside biochemistry, chemical biology, genetics, and analytical chemistry. Initial work will combine genetic engineering with comparative genomic/comparative metabolomics to identify key enzymes involved in halogenation and sulfamate formation. Since these perform valuable transformations, they make promising candidates as biocatalysts for pharmaceutical synthesis. Notably, kinetic and substrate/reaction characterization of these enzymes will be explored test the feasibly of using these enzymes for alternative synthesis of existing nucleoside analog therapeutics. As a subsequent goal, this work will also explore how ‘modular’ biosynthesis of these nucleoside natural products can be used to rapidly synthesize inhibitors of a wide-range of enzymes. Key innovations here will include combinatorial assays with ribozyme components. Finally, this work will look to integrate bioinformatic/metabolomic/genetic approaches to discover unknown nucleoside analogs made by various bacteria. Specifically, we highlight existing evidence of hybrid gene clusters that make unknown nucleosides. As a general vision, this research program poses that elucidating nucleoside biosynthesis pathways, characterizing enzymes that perform rare biochemistry, and discovering new bioactive nucleosides will expand the repertoire of biocatalytic tools available for making life-saving nucleoside analogs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $397,158 )
2026	2026	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Biomedical Research and Research Training	000	1	3/25/2026	NEW	$397,158
														Subtotal = $397,158

Grand Total All Awards = $397,158

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biosynthesis, discovery, and biocatalytic production of halogenated nucleosides and nucleoside-sulfamates.

Award Number: R35GM162070

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer